363 related articles for article (PubMed ID: 37400675)
1. Neoantigen-specific stem cell memory-like CD4
Brightman SE; Becker A; Thota RR; Naradikian MS; Chihab L; Zavala KS; Ramamoorthy Premlal AL; Griswold RQ; Dolina JS; Cohen EEW; Miller AM; Peters B; Schoenberger SP
Nat Immunol; 2023 Aug; 24(8):1345-1357. PubMed ID: 37400675
[TBL] [Abstract][Full Text] [Related]
2. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
3. High-dose IL-2/CD25 fusion protein amplifies vaccine-induced CD4
Hernandez R; LaPorte KM; Hsiung S; Santos Savio A; Malek TR
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34475132
[TBL] [Abstract][Full Text] [Related]
4. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
[TBL] [Abstract][Full Text] [Related]
5. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa N; Poncette L; Blankenstein T
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
[TBL] [Abstract][Full Text] [Related]
6. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
7. One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication.
Wolf SP; Anastasopoulou V; Drousch K; Diehl MI; Engels B; Yew PY; Kiyotani K; Nakamura Y; Schreiber K; Schreiber H; Leisegang M
Clin Cancer Res; 2024 Apr; 30(8):1642-1654. PubMed ID: 38190111
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
9. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
10. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
Poncette L; Chen X; Lorenz FK; Blankenstein T
J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
[TBL] [Abstract][Full Text] [Related]
11. The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth.
McCaw TR; Li M; Starenki D; Cooper SJ; Liu M; Meza-Perez S; Arend RC; Buchsbaum DJ; Forero A; Randall TD
Cancer Immunol Immunother; 2019 Feb; 68(2):175-188. PubMed ID: 30334128
[TBL] [Abstract][Full Text] [Related]
12. Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression.
Dolina JS; Lee J; Brightman SE; McArdle S; Hall SM; Thota RR; Zavala KS; Lanka M; Ramamoorthy Premlal AL; Greenbaum JA; Cohen EEW; Peters B; Schoenberger SP
J Clin Invest; 2023 Sep; 133(17):. PubMed ID: 37655661
[TBL] [Abstract][Full Text] [Related]
13. Reactivation of low avidity tumor-specific CD8
Sugiyarto G; Lau D; Hill SL; Arcia-Anaya D; Boulanger DSM; Parkes E; James E; Elliott T
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586767
[TBL] [Abstract][Full Text] [Related]
14. Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help.
Monjazeb AM; Tietze JK; Grossenbacher SK; Hsiao HH; Zamora AE; Mirsoian A; Koehn B; Blazar BR; Weiss JM; Wiltrout RH; Sckisel GD; Murphy WJ
PLoS One; 2014; 9(8):e102709. PubMed ID: 25119341
[TBL] [Abstract][Full Text] [Related]
15. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
[TBL] [Abstract][Full Text] [Related]
16. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
17. Cell surface marker-based capture of neoantigen-reactive CD8
Chatani PD; Lowery FJ; Parikh NB; Hitscherich KJ; Yossef R; Hill V; Gartner JJ; Paria B; Florentin M; Ray S; Bera A; Parkhust M; Robbins P; Krishna S; Rosenberg SA
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258038
[TBL] [Abstract][Full Text] [Related]
18. Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens.
Bekri S; Rodney-Sandy R; Gruenstein D; Mei A; Bogen B; Castle J; Levey D; Cho HJ
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35190376
[TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
20. Lymphocytes in tumor-draining lymph nodes co-cultured with autologous tumor cells for adoptive cell therapy.
Okamura K; Nagayama S; Tate T; Chan HT; Kiyotani K; Nakamura Y
J Transl Med; 2022 May; 20(1):241. PubMed ID: 35606862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
